PDF(Pubmed)
Abstract：
UNASSIGNED: Determining the clinical and subclinical characteristics related to the recurrence status in patients with a thyroid carcinoma has great significance for prognosis, prediction of recurrence and monitoring of treatment outcomes. This study aimed to determine the association between recurrence rate and some characteristics in patients with thyroid carcinoma.
UNASSIGNED: The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.
UNASSIGNED: Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (P = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (P = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (P = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (P = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (P = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (P = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, P = 0.04).
UNASSIGNED: There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.
UNASSIGNED: The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.
UNASSIGNED: Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (P = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (P = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (P = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (P = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (P = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (P = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, P = 0.04).
UNASSIGNED: There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.
摘要：
■确定甲状腺癌患者复发状态相关的临床和亚临床特征对预后具有重要意义,预测复发和监测治疗结果。本研究旨在确定甲状腺癌患者复发率与某些特征之间的关系。
■本研究采用描述性方法对103军医院102例甲状腺癌患者进行纵向随访,河内,越南,从2013年7月到2016年12月。
■单因素分析表明，患者的复发特征与淋巴结转移特征（P=0.026；OR=15；95％CI=1.4-163.2）和BRAFV600E突变状态（P=0.01；OR=3.41；95％CI=1.31-8.88）之间存在相关性。在分析多变量Logistic回归模型时，BRAFV600E基因突变(P=0.032;OR=17.649;95%CI=1.290~241.523)和男性(P=0.036;OR=12.788;95%CI=1.185~137.961)的发生与研究患者复发的发生呈正相关。男性患者的平均复发时间早于女性患者（P=0.02）。BRAFV600E突变组的平均复发时间(31.81±1.14个月)短于无突变组的平均复发时间(57.82±2.08个月)(P=0.01)。BRAFV600E基因突变组的复发风险高于无突变组(HR=9.14,P=0.04)。
■复发与男子气概呈正相关，甲状腺癌患者的淋巴结转移和BRAFV600E突变的发生。
■本研究采用描述性方法对103军医院102例甲状腺癌患者进行纵向随访,河内,越南,从2013年7月到2016年12月。
■单因素分析表明，患者的复发特征与淋巴结转移特征（P=0.026；OR=15；95％CI=1.4-163.2）和BRAFV600E突变状态（P=0.01；OR=3.41；95％CI=1.31-8.88）之间存在相关性。在分析多变量Logistic回归模型时，BRAFV600E基因突变(P=0.032;OR=17.649;95%CI=1.290~241.523)和男性(P=0.036;OR=12.788;95%CI=1.185~137.961)的发生与研究患者复发的发生呈正相关。男性患者的平均复发时间早于女性患者（P=0.02）。BRAFV600E突变组的平均复发时间(31.81±1.14个月)短于无突变组的平均复发时间(57.82±2.08个月)(P=0.01)。BRAFV600E基因突变组的复发风险高于无突变组(HR=9.14,P=0.04)。
■复发与男子气概呈正相关，甲状腺癌患者的淋巴结转移和BRAFV600E突变的发生。
